GENMAB Buy scenarioI am loking to get into a buy at best after the downward trendline is broken and the SMA(89) is crossed to the upside afterwards.
See examples in the past as indicated by my green circles...
Leave a like or comment, please
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
11.3 EUR
583.65 M EUR
2.21 B EUR
60.32 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Founded
1998
ISIN
DK0010272202
FIGI
BBG00X8QFKR1
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Watch out for long position in GenmabGenmab has reached an important area, which before in time have been a good time to start a long postion.
Genmap Correction -40 %I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.
Genmab is a era done ?I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)
in the stockHello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)
Inverse Cup and handle on the weekly $GMABInverse Cup and handle on the weekly $GMAB
- Inverse Cup and handle on the weekly
- VPVR acting as resistance
- Waiting for a trigger
Interesting cup with handle developmentLooks like we have a cup with handle. Potential target 3600-3800
Genmab opportunitysteamloss in the Genmab stock will likely fuel a new rush.
1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time?
2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GMAB is featured.
Frequently Asked Questions
The current price of GMAB is 204.7 EUR — it has increased by 0.58% in the past 24 hours. Watch GENMAB AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange GENMAB AS stocks are traded under the ticker GMAB.
GMAB stock has fallen by −3.41% compared to the previous week, the month change is a −2.64% fall, over the last year GENMAB AS has showed a −24.41% decrease.
We've gathered analysts' opinions on GENMAB AS future price: according to them, GMAB price has a max estimate of 457.79 EUR and a min estimate of 265.45 EUR. Watch GMAB chart and read a more detailed GENMAB AS stock forecast: see what analysts think of GENMAB AS and suggest that you do with its stocks.
GMAB reached its all-time high on Dec 5, 2022 with the price of 445.6 EUR, and its all-time low was 204.1 EUR and was reached on Nov 1, 2024. View more price dynamics on GMAB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GMAB stock is 2.30% volatile and has beta coefficient of 0.10. Track GENMAB AS stock price on the chart and check out the list of the most volatile stocks — is GENMAB AS there?
Today GENMAB AS has the market capitalization of 13.19 B, it has decreased by −1.46% over the last week.
Yes, you can track GENMAB AS financials in yearly and quarterly reports right on TradingView.
GENMAB AS is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
GMAB earnings for the last quarter are 2.90 EUR per share, whereas the estimation was 2.86 EUR resulting in a 1.64% surprise. The estimated earnings for the next quarter are 2.84 EUR per share. See more details about GENMAB AS earnings.
GENMAB AS revenue for the last quarter amounts to 722.71 M EUR, despite the estimated figure of 672.09 M EUR. In the next quarter, revenue is expected to reach 757.32 M EUR.
GMAB net income for the last quarter is 188.37 M EUR, while the quarter before that showed 177.20 M EUR of net income which accounts for 6.30% change. Track more GENMAB AS financial stats to get the full picture.
No, GMAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 2.20 K employees. See our rating of the largest employees — is GENMAB AS on this list?
Like other stocks, GMAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENMAB AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENMAB AS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENMAB AS stock shows the sell signal. See more of GENMAB AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.